Key facts
- This page summarizes Albert Agro's Form 4 filing for GRI BIO, Inc. (GRI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Apr 2023, 18:29.
Albert Agro - 21 Apr 2023 Form 4 Insider Report for GRI BIO, Inc. (GRI)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- GRI
- Reported as of
- 21 Apr 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Leanne Kelly, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Albert Agro filed Form 4 for GRI BIO, Inc. (GRI) on 24 Apr 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GRI
transaction
Common Stock
Award
- Transaction value
- Shares
- +172,189
- Change %
- Price
- Shares after
- 172,189
- Date
- 21 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Received in exchange for 4,600,000 shares of common stock of GRI Bio, Inc. ("GRI"), pursuant to the Agreement and Plan of Merger, dated December 13, 2022, by and among Vallon Pharmaceuticals, Inc. (the "Company"), Vallon Merger Sub, Inc. and GRI Bio, Inc. (the "Merger"). Per the terms of the Merger, each share of GRI common stock was converted into the right to receive 0.0374 shares of the Company's common stock. In connection with the Merger, the Company effected a reverse stock split of the Company's common stock at a ratio of 1-for-30 (the "Reverse Split"). Unless noted otherwise, all references to share amounts in this Form 4 reflect the Reverse Split.